Monday, 1 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Best Ally in the fight against corruption
    Best Ally in the fight against corruption
    31/08/2025
    SANY Reports Strong First Half 2025 Results, Delivering Profitable Growth
    SANY Reports Strong First Half 2025 Results, Delivering Profitable Growth
    31/08/2025
    Bybit x Santiment DeFi Report: Platform Tokens Shine As MNT Sees Over M Whale Transactions
    Bybit x Santiment DeFi Report: Platform Tokens Shine As MNT Sees Over $1M Whale Transactions
    30/08/2025
    Wonderful Indonesia Shines at ITB India 2025: From Bali to Beyond
    Wonderful Indonesia Shines at ITB India 2025: From Bali to Beyond
    30/08/2025
    Rethink Light, Reimagine Style — Olight Unveils ArkPro Series with Groundbreaking Pure Flood
    Rethink Light, Reimagine Style — Olight Unveils ArkPro Series with Groundbreaking Pure Flood
    29/08/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • global
  • Business
  • july
  • today
  • announced
  • aug
  • company
  • Tech
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

GlobeNews Wire
Last updated: 17/06/2025 2:52 PM
GlobeNews Wire
Share
4 Min Read
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs
SHARE
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

June 17, 2025 02:00 ET  | Source: Orion Oyj

ORION CORPORATION
PRESS RELEASE
17 JUNE 2025 at 9.00 EEST
        

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs).

Under the extended agreement, Orion gains access to Glykos’ proprietary ADC technologies with the potential to expand into three additional programs in the future, in addition to the three ADC programs outlined in the previous agreement. Orion will be responsible for the target selection, research, development, and commercialization of up to three next-generation ADCs, with a focus on solid tumors.

The financial terms of the extended agreement for the three new ADC projects are the same as in the original agreement for the first three projects. Glykos is entitled to milestone payments related to the development of the ADCs and product sales. Glykos is also entitled to receive royalties from the commercial sales generated by the three ADC programs.

“This successful collaboration with Glykos allows us to continue leveraging their advanced ADC technology and underscores our commitment to developing new treatment options for cancer patients,” said Professor Outi Vaarala, Executive Vice President, Innovative Medicines and Research & Development at Orion.

“The extension of our agreement with Orion highlights the potential of our ADC technology. We are excited to expand our collaboration with Orion, whose expertise in cancer therapies and strong clinical development capabilities are crucial for bringing new, effective treatments to cancer patients,” said Juhani Saarinen, CEO of Glykos.

About Orion
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion’s net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion’s A and B shares are listed on Nasdaq Helsinki

About Glykos
Glykos, focusing on antibody-drug conjugates (ADCs), is dedicated to revolutionizing cancer treatment. Glykos’ proprietary hydrophilic payload and linker technology addresses ADC limitations, offering benefits of high efficacy, increased tolerability, excellent pharmacokinetics, and optimized conjugation with any monoclonal antibody. Focused on expanding the therapeutic index, we aim to extend survival and enhance the quality of life for cancer patients. For more information, please visit www.glykos.fi.

Orion Corporation

Contact person:
Antti Haapalinna, Vice President, External Science and Partnering, R&D, Orion Corporation
tel. +358 50 966 7670
e-mail: antti.haapalinna@orionpharma.com
                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

WinnerMining launches new energy power project.
UMC Reports Sales for June 2025
ROLLER and Slick City Team Up to Share the Franchise Growth Playbook in Upcoming Webinar
96% of health care executives are “ready and resourced” to use digital health solutions, yet two-thirds say interoperability is “a tough but manageable challenge,” reveals new MIT Technology Review Insights report
Azentio appoints Harikrishnan Venkataramanan as President – ERP to spearhead next phase of innovation and growth
TAGGED:adcsAdventureagreementannouncecollaborationcorporationdevelopmenteest        extensionglykosjunelicensingnextgenerationorionoyjpressreleaseResearchsource
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Latest Economy Observer report from Dun & Bradstreet reveals India’s steady rise as inflation eases and financial markets strengthen
News

Latest Economy Observer report from Dun & Bradstreet reveals India’s steady rise as inflation eases and financial markets strengthen

09/06/2025
First IPO Under GIFT City’s IFSC Regime – DRHP Filed; Executive Education Platform Leads the Charge
Tech

First IPO Under GIFT City’s IFSC Regime – DRHP Filed; Executive Education Platform Leads the Charge

23/08/2025
Entrepreneur Nirvaan Birla Releases His Musical Debut with Soulful Track Shankaraa, a Tribute to Lord Shiva on Shravan
Health

Entrepreneur Nirvaan Birla Releases His Musical Debut with Soulful Track Shankaraa, a Tribute to Lord Shiva on Shravan

26/07/2025

Shanghai Electric Showcases Cutting-Edge Green and Smart Technology at Carbon Neutrality Expo 2025, Accelerating the Transition to a Zero-Carbon World

10/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?